Completed PHASE2 INTERVENTIONAL NCT01369420

NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer

A Safety Evaluation of the NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer - A Pilot Study

Sponsor: Angiodynamics, Inc.

Conditions Pancreatic Adenocarcinoma

Interventions NanoKnife Low Energy Direct Current (LEDC) System Ablation

Updated 6 times since 2017 Last updated: Nov 7, 2016 Started: May 31, 2011 Primary completion: Dec 31, 2011 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pancreatic Adenocarcinoma, this trial is completed. The trial is conducted by Angiodynamics, Inc. and has accumulated 6 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Angiodynamics, Inc.

Data source: Angiodynamics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Verona, Italy